Dataset Information


Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.

ABSTRACT: BACKGROUND:Symptomatic patients with chronic obstructive pulmonary disease (COPD) and low exacerbation risk still have disease instability, which can be improved with better bronchodilation. We evaluated two long-acting bronchodilators individually and in combination on reducing exacerbation risk and the potential impact of concurrent medication in these patients. METHODS:Integrated post hoc intent-to-treat (ITT) analysis of data from two large 24-week, randomized placebo (PBO)-controlled trials (NCT01313637, NCT01313650). Symptomatic patients with moderate-to-very-severe COPD with/without an exacerbation history were randomized (2:3:3:3) to once-daily: PBO, umeclidinium/vilanterol (UMEC/VI 62.5/25??g [NCT01313650] or 125/25??g [NCT01313637]), UMEC (62.5 [NCT01313650] or 125??g [NCT01313637]) or VI (25??g) via the ELLIPTA inhaler. Medication subgroups were segmented by treatment status at screening: a) maintenance-naïve or on maintenance medications, b) inhaled corticosteroid [ICS]-free or ICS-treated, c) low or high albuterol use based on median run-in use (

PROVIDER: S-EPMC6434823 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC4579251 | BioStudies
| S-EPMC7605201 | BioStudies
| S-EPMC5126189 | BioStudies
| S-EPMC5785849 | BioStudies
| S-EPMC5934530 | BioStudies
| S-EPMC4918053 | BioStudies
| S-EPMC6182634 | BioStudies
| S-EPMC4869636 | BioStudies
| S-EPMC7607727 | BioStudies
| S-EPMC7286387 | BioStudies